Alkermes (ALKS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.57
- Estimate
- $0.25
- Surprise
- +130.9%
- Revenue (period 2026-09-30)
- $480.1M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Alkermes (ALKS) beat the $0.25 estimate with adjusted EPS of $0.57 — a large 130.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALKS Hold at 5.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +130.9% surprise compares with a +333.2% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Overbought (RSI 82)
- Reward/Risk 0.7:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $45.69
- Price target
- $50.59
- Stop
- $42.49
- Upside to target
- +10.7%
- Reward-to-risk
- 0.7:1
Risk check: RSI 82 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
ALKS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $7.67B
- P/E (fwd)
- 25.3
- 52-week range
- $27.00–$55.67
- Off 52-week high
- 17.9%
- RSI (14)
- 82
- Volume vs avg
- 1.24×
- Score today
- 5.5/10